best peptides for long covid FAQ

Focus the protocol on BPC-157 and thymosin beta-4 rather than neurotropic peptides. Vascular-predominant Long COVID. Orthostatic intolerance, palpitations, poor perfusion. Responds to angiogenesis and endothelial repair mechanisms. BPC-157 restores nitric oxide signaling within 10–14 days in animal wound healing models, and TB-500 reduces inflammatory cytokines that perpetuate vascular inflammation. Combining both targets the problem from complementary angles: BPC-157 rebuilds vessel integrity while TB-500 clears the inflammatory environment preventing healing. Research dosing typically runs 12–16 weeks before assessing vascular function improvements.

Target mitochondrial function with MOTS-c rather than continuing vascular or neurological peptides. Isolated fatigue post-recovery suggests the cellular energy machinery hasn't restored normal oxidative phosphorylation. MOTS-c directly activates AMPK, the enzyme that signals mitochondria to increase ATP production through fat oxidation instead of glycolysis. Research dosing uses 5–15 mg subcutaneous 2–3 times weekly. Exercise capacity improvements in metabolic studies appear at 6–8 weeks. Our team has seen this pattern frequently. Patients who cleared brain fog and vascular symptoms but plateau at 70% energy often have residual mitochondrial impairment that energy-focused peptides can address.

Prioritize semax and selank over mitochondrial peptides. Brain fog without significant fatigue suggests the primary dysfunction is neuroinflammatory rather than metabolic. Semax crosses the blood-brain barrier and elevates BDNF. The molecule responsible for synaptic plasticity and memory consolidation. Selank reduces the inflammatory cytokines (IL-6, TNF-alpha) that impair hippocampal function. Russian research protocols use semax 300–600 mcg intranasal daily for 30–60 days, often paired with selank at the same dose for synergistic anti-inflammatory effects. Cognitive improvements typically emerge at week 4–6 as neuroplasticity mechanisms engage.

Start with immune restoration before addressing neurological symptoms. Chronic immune activation and elevated inflammatory cytokines drive neuroinflammation. Treating the upstream immune dysfunction often reduces downstream cognitive issues without direct neuroprotective intervention. Thymalin should be the first-line research compound, with Cerebrolysin or Dihexa added after 4–6 weeks if cognitive symptoms persist despite normalized inflammatory markers. Combining immune and neuroprotective peptides simultaneously can obscure which intervention is driving improvement and complicates dosing adjustments.

BPC-157 is the mechanistically optimal starting point for vascular and mitochondrial dysfunction. The compound's ability to restore endothelial function and improve microvascular density addresses the root cause of exercise intolerance. Inadequate oxygen and nutrient delivery to tissues. Pair BPC-157 with mitochondrial support (CoQ10, NAD+ precursors, PQQ) to address both vascular and cellular energy deficits. Fatigue in long COVID is rarely a single-origin problem. It's the downstream result of vascular injury, mitochondrial impairment, and immune activation compounding each other.

Peptide-based interventions operate through different mechanisms than standard protocols (rest, pacing, antidepressants, physical therapy). If you've plateaued on conventional care, it likely means your pathology. Immune dysregulation, endothelial damage, or neuroinflammation. Requires targeted molecular intervention rather than symptom management. Research peptides address these mechanisms directly, but they require proper sourcing, dosing, and monitoring to assess efficacy. The gap between standard care and peptide protocols is mechanistic specificity. One addresses symptoms, the other addresses root pathology.